GMDA - Gamida Cell's Blood Cancer Candidate Shows Encouraging Anti-Tumor Activity In Heavily Pretreated Patients | Benzinga
Gamida Cell Ltd (NASDAQ: GMDA) released new early data in 10 patients with CD20-positive non-Hodgkin lymphoma enrolled in the first three cohorts in an ongoing Phase 1 study of natural killer (NK) cell therapy candidate GDA-201.
The study is designed to evaluate safety and determine the maximum tolerated dose.
Enrolled patients were heavily pretreated with a median of six prior lines of therapy, including CAR-T cell therapy ...